CEO sells $227,400 in shares. Adam S. Grossman, President and CEO of ADMA Biologics Inc (NASDAQ: ADMA), sold 15,000 shares at $15.16 per share on March 17, 2026, according to a Form 4 filing with the SEC. The transaction reduced his direct holdings to 2,118,777 shares.
Option exercise accompanies sale. The same day, Lawrence P. Guiheen exercised options on 30,000 shares at $3.66 per share, bringing his ownership to 135,520 shares. The two filings represent a combined $337,200 in transaction value across 45,000 shares.
Selling dominates recent insider activity. Over the past six months, ADMA insiders have sold 146,192 shares while purchasing just 21,000 shares, resulting in net selling of 125,192 shares. Grossman’s sale extends this pattern of net insider disposition.
Institutional ownership remains concentrated. BlackRock Inc. leads institutional holders with 36.3 million shares representing 0.15% of its portfolio, followed by Vanguard Group with 20.9 million shares. State Street Corporation holds 13.6 million shares, while Invesco and Sachem Head Capital Management each control approximately 11.4-11.8 million shares.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.